Cartesian Therapeutics, Inc. Debt Conversion, Converted Instrument, Amount
Cartesian Therapeutics, Inc. (RNAC) reported Debt Conversion, Converted Instrument, Amount of $0 for the 9-month period ending 2018-09-30, per its 10-Q filed 2018-11-08.
Discontinued › Cash Flow › Financing Activities
us-gaap:DebtConversionConvertedInstrumentAmount1 · last filed 2018-11-08
- Cartesian Therapeutics, Inc. debt conversion, converted instrument, amount for the quarter ending 2017-12-31 was -$7.00K.
- Cartesian Therapeutics, Inc. debt conversion, converted instrument, amount for the quarter ending 2017-09-30 was -$2.82M.
- Cartesian Therapeutics, Inc. debt conversion, converted instrument, amount for the quarter ending 2016-12-31 was $0.00.
- Cartesian Therapeutics, Inc. debt conversion, converted instrument, amount for the quarter ending 2015-12-31 was $0.00.
- Cartesian Therapeutics, Inc. debt conversion, converted instrument, amount for fiscal 2017 was $0.00.
- Cartesian Therapeutics, Inc. debt conversion, converted instrument, amount for fiscal 2016 was $0.00, a 100.00% decline from fiscal 2015.
- Cartesian Therapeutics, Inc. debt conversion, converted instrument, amount for fiscal 2015 was $7.29M.
- Cartesian Therapeutics, Inc. debt conversion, converted instrument, amount for fiscal 2014 was $0.00.
| Period end | Debt Conversion, Converted Instrument, Amount 3 month | Debt Conversion, Converted Instrument, Amount 6 month | Debt Conversion, Converted Instrument, Amount 9 month | Debt Conversion, Converted Instrument, Amount 12 month |
|---|---|---|---|---|
| 2018-09-30 | $0.00 10-Q · filed 2018-11-08 | |||
| 2017-12-31 | -$7.00K derived: 10-K 12 month − 10-Q 9 month · filed 2018-03-15 | -$2.83M derived: sum of 2 quarters · filed 2018-11-08 | $0.00 10-K · filed 2018-03-15 | |
| 2017-09-30 | -$2.82M derived: 10-Q 9 month − 10-Q 6 month · filed 2018-11-08 | $7.00K 10-Q · filed 2018-11-08 | ||
| 2017-06-30 | $2.83M 10-Q · filed 2017-08-11 | |||
| 2016-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2018-03-15 | $0.00 10-K · filed 2018-03-15 | ||
| 2016-09-30 | $0.00 10-Q · filed 2017-11-07 | |||
| 2015-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2018-03-15 | $7.29M 10-K · filed 2018-03-15 | ||
| 2015-09-30 | $7.29M 10-Q · filed 2016-11-10 | |||
| 2014-12-31 | $0.00 10-K · filed 2017-03-28 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Keros Therapeutics, Inc. (KROS) | United States | $0.229B | -2.55 |
| SIGA TECHNOLOGIES INC (SIGA) | United States | $0.234B | -93.33 |
| NATURES SUNSHINE PRODUCTS INC (NATR) | United States | $0.228B | 20.51 |
| Sionna Therapeutics, Inc. (SION) | United States | $0.236B | -20.37 |
| Camp4 Therapeutics Corp (CAMP) | United States | $0.240B | -2.12 |
| Whitehawk Therapeutics, Inc. (WHWK) | United States | $0.221B | |
| MACROGENICS INC (MGNX) | United States | $0.242B | -20.11 |
| Cue Biopharma, Inc. (CUE) | United States | $0.243B | -1.01 |
| Entrada Therapeutics, Inc. (TRDA) | United States | $0.243B | -1.73 |
| Eledon Pharmaceuticals, Inc. (ELDN) | United States | $0.219B | -3.23 |